Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study
Patient:innen mit Opioidgebrauchsstörung, die sich für eine Behandlung mit Extended-Release-Naltrexon entscheiden: 6-monatige naturalistische Studie
European Addiction Research · 04.11.2024 · 1-12
DOI: 10.1159/000541431 ↗Auf einen Blick
In einer 24-wöchigen prospektiven Kohortenstudie mit 161 Personen mit Opioidgebrauchsstörung war die Behandlungsbindung unter XR-NTX hoch. Der Opioidkonsum nahm ab; schwerwiegende unerwünschte Ereignisse traten nicht behandlungsbedingt auf.
Fragestellung
Welche Behandlungsergebnisse zeigt XR-NTX bei Personen mit Opioidgebrauchsstörung in einem Setting mit freier Wahl gegenüber OAT?
Methode
Prospektive offene Kohortenstudie über 24 Wochen in 5 Krankenhäusern in Norwegen; ambulant. XR-NTX i.m. alle 4 Wochen; erfasst wurden Behandlungsbindung, Konsum und unerwünschte Ereignisse.
Ergebnisse
161 Teilnehmende, mittleres Alter 38 Jahre, 24 % Frauen; 138 erhielten mindestens 1 Dosis. Mittlere Behandlungsdauer 18,1 Wochen (95 %-KI 16,8–19,4); 84/138 (60,9 %) schlossen 24 Wochen ab. Opioide nahmen ab (p < 0,001); kein schweres AE direkt mit XR-NTX verbunden.
Schlussfolgerung der Autor:innen
Die Studie zeigte hohe Behandlungsbindung, weniger Opioidkonsum und wenig andere illegale Substanzen sowie Alkohol. Bei Abschluss der 24 Wochen waren Opioidkonsum und Zufriedenheit günstiger als bei vorzeitigem Abbruch.
Kernaussagen
- Mittlere Behandlungsdauer: 18,1 Wochen (95 %-KI 16,8–19,4)
- 84/138 (60,9 %) schlossen 24 Wochen ab
- Keine schweren unerwünschten Ereignisse direkt mit XR-NTX verbunden
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift European Addiction Research, online erschienen am 04.11.2024. Verfasst von Ida Halvorsen Brenna und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Naltrexone, Narcotic Antagonists, Opioid-Related Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Introduction
The treatment efficacy of extended-release naltrexone (XR-NTX) for opioid use disorder (OUD) has been demonstrated in several studies, but not in naturalistic settings where opioid agonist treatment (OAT) is freely accessible. This study aimed to examine the different treatment outcomes of XR-NTX in a setting where the participants freely chose XR-NTX as a treatment option instead of OAT.
Methods
This was a 24-week open-label clinical prospective cohort study conducted in an outpatient setting at five hospitals in Norway. The study included 161 participants aged 18–65 years with OUD. Intramuscular injections of XR-NTX were administered every 4 weeks for 24 weeks. Measurements included retention in treatment, reasons for treatment discontinuation, days of use of opioids, other illicit substances and alcohol, level of heroin craving, treatment satisfaction, and adverse events (AEs).
Results
Of 161 included participants, the mean age was 38 years, and 24% were women; 138 received at least one dose of the study medication (modified intention-to-treat [MITT] population), and mean time in treatment was 18.1 weeks (95% CI: 16.8–19.4). The majority of the MITT population (84; 60.9%) completed 24 weeks of treatment in the study. There was a significant decrease in the overall use of opioids (p < 0.001) and the use of alcohol, and other illicit substances were low. The participants generally reported high treatment satisfaction and low heroin cravings. Those who completed the 24 weeks of treatment reported significantly fewer days of opioid use (p < 0.001) and higher treatment satisfaction (p < 0.001) than those who discontinued treatment before 24 weeks. No serious AEs were directly related to XR-NTX use.
Conclusion
This study demonstrated high retention rates, decreased opioid use, and low use of other illicit substances and alcohol. Participants also reported low cravings for heroin and high treatment satisfaction. Completion of the full 24-week treatment resulted in lower opioid use and increased treatment satisfaction compared to those who discontinued treatment before 24 weeks. The observed higher retention and reduced opioid use, compared to other studies, may be attributed to participants’ strong motivation for opioid abstinence facilitated by XR-NTX treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Psychology, Faculty of Psychology, University of Bergen, Bergen, Norway.
- Department of Research and Development in Mental Health, Akershus University Hospital, Lørenskog, Norway.
- Institute of Clinical Medicine, University of Oslo, Blindern, Norway.
- Institute of Clinical Medicine, Campus Ahus, University of Oslo, Blindern, Norway.
- Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
Zitieren
APA
Brenna, I. H., Waleur, K. M., Benth, J. Š., Solli, K. K., Mordal, J., Løberg, E. M., Weimand, B., & Tanum, L. (2024). Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study. European Addiction Research, 1-12. https://doi.org/10.1159/000541431
Vancouver
Brenna IH, Waleur KM, Benth JŠ, Solli KK, Mordal J, Løberg EM, et al. Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study. European Addiction Research. 2024:1-12. doi:10.1159/000541431
BibTeX
@article{Brenna2024,
author = {Brenna, Ida Halvorsen and Waleur, Karin Merethe and Benth, Jūratė Šaltytė and Solli, Kristin K and Mordal, Jon and Løberg, Else-Marie and Weimand, Bente and Tanum, Lars},
title = {Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study},
journal = {European Addiction Research},
year = {2024},
pages = {1--12},
doi = {10.1159/000541431}
}
EUVIMED